REFERENCES
1. Feng J, Polychronidis G, Heger U, Frongia G, Mehrabi A, Hoffmann K. Incidence trends and survival prediction of hepatoblastoma in children: a population-based study. Cancer Commun (Lond) 2019;39:62.
2. Czauderna P, Lopez-Terrada D, Hiyama E, Häberle B, Malogolowkin MH, Meyers RL. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr 2014;26:19-28.
3. Allan BJ, Parikh PP, Diaz S, Perez EA, Neville HL, Sola JE. Predictors of survival and incidence of hepatoblastoma in the paediatric population. HPB (Oxford) 2013;15:741-6.
4. Garber JE, Li FP, Kingston JE, et al. Hepatoblastoma and familial adenomatous polyposis. J Natl Cancer Inst 1988;80:1626-8.
5. Cohen MM Jr. Beckwith-Wiedemann syndrome: historical, clinicopathological, and etiopathogenetic perspectives. Pediatr Dev Pathol 2005;8:287-304.
7. Angelico R, Grimaldi C, Gazia C, et al. How do synchronous lung metastases influence the surgical management of children with hepatoblastoma? Cancers (Basel) 2019;11:1693.
8. Aronson DC, Meyers RL. Malignant tumors of the liver in children. Semin Pediatr Surg 2016;25:265-75.
9. Starzl TE, Marchioro TL, von Kaulla KN, et al. Homotransplantation of the liver in humans. Surg Gynecol Obstet 1963;117:659-76.
10. Ezekian B, Mulvihill MS, Schroder PM, et al. Improved contemporary outcomes of liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma. Pediatr Transplant 2018;22:e13305.
11. Otte JB, Pritchard J, Aronson DC, et al. International Society of Pediatric Oncology (SIOP). Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 2004;42:74-83.
12. Meyers RL. Liver transplantation in the management of unresectable hepatoblastoma in children. Front Biosci 2012;E4:1293.
13. Khaderi S, Guiteau J, Cotton RT, O’Mahony C, Rana A, Goss JA. Role of liver transplantation in the management of hepatoblastoma in the pediatric population. World J Transplant 2014;4:294-8.
14. Squires RH, Ng V, Romero R, et al. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Hepatology 2014;60:362-98.
15. Sindhi R, Rohan V, Bukowinski A, et al. Liver transplantation for pediatric liver cancer. Cancers (Basel) 2020;12:720.
16. Ziogas IA, Benedetti DJ, Wu WK, et al. Management of hepatoblastoma in the United States: can we do better? Surgery 2021;170:579-86.
17. Yamada Y, Ohno M, Fujino A, et al. Fluorescence-guided surgery for hepatoblastoma with indocyanine green. Cancers (Basel) 2019;11:1215.
18. Yamamichi T, Oue T, Yonekura T, et al. Clinical application of indocyanine green (ICG) fluorescent imaging of hepatoblastoma. J Pediatr Surg 2015;50:833-6.
19. Kitagawa N, Shinkai M, Mochizuki K, et al. Navigation using indocyanine green fluorescence imaging for hepatoblastoma pulmonary metastases surgery. Pediatr Surg Int 2015;31:407-11.
20. Takahashi N, Yamada Y, Hoshino K, et al. Living donor liver re-transplantation for recurrent hepatoblastoma in the liver graft following complete eradication of peritoneal metastases under indocyanine green fluorescence imaging. Cancers (Basel) 2019;11:730.
21. Meyers AB, Towbin AJ, Geller JI, Podberesky DJ. Hepatoblastoma imaging with gadoxetate disodium-enhanced MRI - typical, atypical, pre- and post-treatment evaluation. Pediatr Radiol 2012;42:859-66.
22. Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma - results from the International Society of Paediatric Oncology (SIOP) Study SIOPEL 1. European Journal of Cancer 2000;36:1418-25.
23. Zsíros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 2010;28:2584-90.
24. Zsiros J, Brugieres L, Brock P, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. The Lancet Oncology 2013;14:834-42.
25. Perilongo G, Shafford E, Maibach R, et al. International Society of Paediatric Oncology-SIOPEL 2. Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology - SIOPEL 2. Eur J Cancer 2004;40:411-21.
26. Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol 2000;18:3819-28.
27. Aronson DC, Weeda VB, Maibach R, et al. Childhood Liver Tumour Strategy Group (SIOPEL). Microscopically positive resection margin after hepatoblastoma resection: what is the impact on prognosis? Eur J Cancer 2019;106:126-32.
28. Schnater JM, Aronson DC, Plaschkes J, et al. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group (SIOPEL-1). Cancer 2002;94:1111-20.
29. Katzenstein HM, Furman WL, Malogolowkin MH, et al. Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: a report from the Children’s Oncology Group AHEP0731 study committee. Cancer 2017;123:2360-7.
30. O’neill AF, Towbin AJ, Krailo MD, Xia C, Gao Y, et al. Characterization of pulmonary metastases in children with hepatoblastoma treated on children’s oncology group protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): a report from the children’s oncology group. J Clin Oncol 2017;35:3465-73.
31. Katzenstein HM, Chang KW, Krailo M, et al. Children’s Oncology Group. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children’s Oncology Group. Cancer 2009;115:5828-35.
32. Sasaki F, Matsunaga T, Iwafuchi M, et al. (Japanese Study Group for Pediatric Liver Tumor). Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: a report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg 2002;37:851-6.
33. Hishiki T, Matsunaga T, Sasaki F, et al. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT. Pediatr Surg Int 2011;27:1-8.
34. Hishiki T, Watanabe K, Ida K, et al. The role of pulmonary metastasectomy for hepatoblastoma in children with metastasis at diagnosis: results from the JPLT-2 study. J Pediatr Surg 2017;52:2051-5.
35. Hiyama E, Hishiki T, Watanabe K, et al. Resectability and tumor response after preoperative chemotherapy in hepatoblastoma treated by the Japanese Study Group for Pediatric Liver Tumor (JPLT)-2 protocol. J Pediatr Surg 2016;51:2053-7.
36. Schweinitz D, Hecker H, Schmidt-von-arndt G, Harms D. Prognostic factors and staging systems in childhood hepatoblastoma. Int J Cancer 1997;74:593-9.
37. Fuchs J, Rydzynski J, Von Schweinitz D, et al. Study Committee of the Cooperative Pediatric Liver Tumor Study Hb 94 for the German Society for Pediatric Oncology and Hematology. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 2002;95:172-82.
38. Yang T, Whitlock RS, Vasudevan SA. Surgical management of hepatoblastoma and recent advances. Cancers (Basel) 2019;11:1944.
39. Towbin AJ, Meyers RL, Woodley H, et al. 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol 2018;48:536-54.
40. Meyers RL, Maibach R, Hiyama E, et al. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children’s Hepatic tumors International Collaboration. The Lancet Oncology 2017;18:122-31.
41. Paediatric Hepatic International Tumour Trial PHITT.; 2018. Available from: https://www.birmingham.ac.uk/Documents/college-mds/trials/crctu/phitt/Protocol/Current/PHITT-Protocol-version-3-0-17Oct2018.pdf [Last accessed on 15 Sep 2022].
42. Ziogas IA, Ye F, Zhao Z, et al. Population-based analysis of hepatocellular carcinoma in children: identifying optimal surgical treatment. J Am Coll Surg 2020;230:1035-1044.e3.
43. Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 2009;361:1662-70.
44. Lake CM, Tiao GM, Bondoc AJ. Surgical management of locally-advanced and metastatic hepatoblastoma. Semin Pediatr Surg 2019;28:150856.
45. Otte JB. Pediatric liver transplantation: personal perspectives on historical achievements and future challenges. Liver Transpl 2016;22:1284-94.
46. Trobaugh-Lotrario AD, Meyers RL, Tiao GM, Feusner JH. Pediatric liver transplantation for hepatoblastoma. Transl Gastroenterol Hepatol 2016;1:44.
47. Czauderna P, Garnier H. Hepatoblastoma: current understanding, recent advances, and controversies. F1000Res 2018;7:53.
48. Moon SB, Shin HB, Seo JM, Lee SK. Hepatoblastoma: 15-year experience and role of surgical treatment. J Korean Surg Soc 2011;81:134-40.
49. Yankol Y, Fernandez LA, Kanmaz T, et al. Results of pediatric living donor compared to deceased donor liver transplantation in the PELD/MELD era: experience from two centers on two different continents. Pediatr Transplant 2016;20:72-82.
50. Kwong AJ, Kim WR, Lake JR, et al. OPTN/SRTR 2019 annual data report: liver. Am J Transplant 2021;21 Suppl 2:208-315.
51. Wu WK, Ziogas IA, Matsuoka LK, et al. Waitlist mortality and post-liver transplant outcomes of pediatric patients with hepatocellular carcinoma and hepatoblastoma in the United States. Pediatr Blood Cancer 2022;69:e29425.
52. Miller CM, Quintini C, Dhawan A, et al. The international liver transplantation society living donor liver transplant recipient guideline. Transplantation 2017;101:938-44.
53. Zhang R, Zhu ZJ, Sun LY, et al. Outcomes of pediatric liver transplantation: deceased donor liver transplantation vs living donor liver transplantation. Transplant Proc 2018;50:3601-5.
54. Kasahara M, Sakamoto S, Fukuda A. Pediatric living-donor liver transplantation. Semin Pediatr Surg 2017;26:224-32.
55. Barbetta A, Butler C, Barhouma S, et al. Living donor versus deceased donor pediatric liver transplantation: a systematic review and meta-analysis. Transplant Direct 2021;7:e767.
56. Patel MS, Mohamed Z, Ghanekar A, et al. Living donor liver paired exchange: a North American first. Am J Transplant 2021;21:400-4.
57. Mishra A, Lo A, Lee GS, et al. Liver paired exchange: can the liver emulate the kidney? Liver Transpl 2018;24:677-86.
58. Non-directed Liver Donation. Patient Care. Available from: https://weillcornell.org/services/liver-transplantation-hepatobiliary-pancreatic-surgery/living-donor-liver-transplantation-program/non-directed-liver-donation [Last accessed on 13 Sep 2022].
59. Herbst LR, Herrick-Reynolds K, Bowles Zeiser L, et al. The landscape of nondirected living liver donation in the United States. Transplantation 2022;106:1600-8.
60. Live and Let Live. Montefiore Einstein Center for Transplantation. Available from: https://liveandletlive.montefiore.org/ [Last accessed on 13 Sep 2022].
61. Montefiore Einstein Center for Transplantation - Heart, Liver, Kidney, Pancreatic Transplantation - New York City. Available from: https://www.montefiore.org/transplantation [Last accessed on 13 Sep 2022].
62. Austin MT, Feurer ID, Chari RS, Gorden DL, Wright JK, Pinson CW. Survival after pediatric liver transplantation: why does living donation offer an advantage? Arch Surg 2005;140:465-70; discussion 470.
63. Khalaf H. Vascular complications after deceased and living donor liver transplantation: a single-center experience. Transplant Proc 2010;42:865-70.
64. Ziogas IA, Alexopoulos SP, Matsuoka LK, et al. Living vs deceased donor liver transplantation in cholestatic liver disease: an analysis of the OPTN database. Clin Transplant 2020;34:e14031.
65. Otte JB, de Ville de Goyet J, Reding R. Liver transplantation for hepatoblastoma: indications and contraindications in the modern era. Pediatr Transplant 2005;9:557-65.
66. Meyers RL, Katzenstein HM, Krailo M, McGahren ED 3rd, Malogolowkin MH. Surgical resection of pulmonary metastatic lesions in children with hepatoblastoma. J Pediatr Surg 2007;42:2050-6.
67. Yamada Y, Hoshino K, Mori T, et al. Metastasectomy of hepatoblastoma utilizing a novel overlay fluorescence imaging system. J Laparoendosc Adv Surg Tech A 2018;28:1152-5.
68. Graaf W, Bennink RJ, Veteläinen R, van Gulik TM. Nuclear imaging techniques for the assessment of hepatic function in liver surgery and transplantation. J Nucl Med 2010;51:742-52.
69. Talakić E, Janek E, Mikalauskas S, Schemmer P. Liver transplantation in malignancies: A comprehensive and systematic review on oncological outcome. Visc Med 2021;37:302-314.
70. Isono K, Ohya Y, Lee KJ, et al. Pretransplant trends in α-fetoprotein levels as a predictor of recurrence after living donor liver transplantation for unresectable hepatoblastoma: a single-institution experience. Pediatr Transplant 2018;22:e13221.
71. Umeda K, Okajima H, Kawaguchi K, et al. Prognostic and therapeutic factors influencing the clinical outcome of hepatoblastoma after liver transplantation: a single-institute experience. Pediatr Transplant 2018;22:e13113.
72. Triana Junco P, Cano EM, Dore M, et al. Prognostic factors for liver transplantation in unresectable hepatoblastoma. Eur J Pediatr Surg 2019;29:28-32.
73. Sakamoto S, Kasahara M, Mizuta K, et al. Japanese Liver Transplantation Society. Nationwide survey of the outcomes of living donor liver transplantation for hepatoblastoma in Japan. Liver Transpl 2014;20:333-46.
74. Malogolowkin MH, Katzenstein HM, Meyers RL, et al. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children’s Oncology Group. J Clin Oncol 2011;29:3301-6.
75. Haas JE, Feusner JH, Finegold MJ. Small cell undifferentiated histology in hepatoblastoma may be unfavorable. Cancer 2001;92:3130-4.
76. Trobaugh-Lotrario AD, Tomlinson GE, Finegold MJ, Gore L, Feusner JH. Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors. Pediatr Blood Cancer 2009;52:328-34.
77. López-Terrada D, Alaggio R, de Dávila MT, et al. Children’s Oncology Group Liver Tumor Committee. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Mod Pathol 2014;27:472-91.
78. Barbetta A, Butler C, Barhouma S, et al. Living donor versus deceased donor pediatric liver transplantation: a systematic review and Meta-analysis. Transplant Direct 2021;7:e767.
79. Henderson ML, Adler JT, Van Pilsum Rasmussen SE, et al. How should social media be used in transplantation? Transplantation 2019;103:573-80.
80. The Facebook Effect: Social Media Dramatically Boosts Organ Donor Registration - 06/18/2013. Available from: https://www.hopkinsmedicine.org/news/media/releases/the_facebook_effect_social_media_dramatically_boosts_organ_donor_registration [Last accessed on 13 Sep 2022].
